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Abstract
Objective. We report the first comparison between rituximab (RTX) and either MMF or CYC pulses in the
treatment of active LN.
Methods. Fifty-four patients with active LN received three methylprednisolone pulses for 3 consecutive
days followed by oral prednisone and RTX 1 g at days 3 and 18 (17 patients) or MMF 22.5 g/day
(17 patients) or six CYC pulses (0.5 g every fortnight) (20 patients). At 4 months MMF, AZA or ciclosporin
were associated to prednisone as a consolidation/maintenance therapy in all groups. The outcomes of the
three groups were compared at 3 and 12 months.
Results. Patients in the RTX group were older, had a longer duration of SLE and LN, had more renal
flares, had higher activity and had higher chronicity indexes at renal biopsy than the other two groups.
Four patients in each group had acute renal dysfunction and 50% had nephrotic syndrome. At 3 months,
proteinuria was reduced by 50% in 58.8% of patients on RTX, in 64.7% on MMF and in 63.1% on CYC.
At 12 months, complete remission was present in 70.6% of patients on RTX, in 52.9% on MMF, and in
65% on CYC. Partial remission was reached in 29.4% on RTX, 41.2% on MMF, and 25% on CYC.
Conclusion. RTX seems to be at least as effective as MMF and CYC pulses in inducing remission.
Considering that patients treated with RTX had more negative renal prognostic factors, this drug should
be considered a viable alternative for the treatment of active LN.
Key words: systemic lupus erythematosus, lupus nephritis, rituximab therapy, cyclophosphamide pulse ther-
apy, mycophenolate therapy.
Introduction
LN is one of the major complications of SLE and is
associated with a high rate of morbidity and mortality.
The current recommended induction treatment for
severe forms of LN is a combination of corticosteroids,
i.v. methylprednisolone pulses (MPPs) followed by high-
dose prednisone, associated with CYC, either adminis-
tered intravenously or orally, or mycophenolate salts
(MMF) [1]. A number of meta-analyses of randomized con-
trolled trials (RCTs) that compared CYC with MMF in pa-
tients with biopsy-proven proliferative LN showed that
MMF is as effective as CYC in achieving remission. The
risk of amenorrhoea, leucopenia and alopecia is lower,
while the risk of diarrhoea is higher with MMF than CYC
[24]. However, few data are available regarding long-
term results of MMF therapy [5] and of MMF treatment
in severe forms of LN [6, 7]. Rituximab (RTX), an anti-
CD20 monoclonal antibody, has emerged as a novel
therapeutic alternative for SLE patients. An RCT of RTX
[the Lupus Nephritis Assessment with Rituximab (LUNAR)
study] [8] failed to show any additional effect of RTX as an
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add-on therapy to the steroidMMF combination for LN
type III/IV in incident patients. Instead, two reviews of non-
controlled studies [9, 10] and two large multicentre retro-
spective studies [11, 12] reported that RTX obtained
complete or partial remission at 12 months in 6774%
of patients with diseases refractory to standard therapy
or with a renal flare of LN. A renal recurrence occurred in
30% of patients within 224 months after administration
of the drug [13]. However, with few exceptions [1416], in
the majority of non-controlled studies RTX was adminis-
tered together with i.v. CYC [1720] or while continuing
the ongoing immunosuppression [2123], and for this
reason the real efficacy and toxicity of RTX in comparison
with conventional therapy is not known.
In this clinical observational study we compared for the
first time the efficacy on renal and extra-renal manifest-
ations and the toxicity of induction therapy with RTX alone
vs CYC pulses and vs MMF in patients with active LN.
Patients and methods
From 2005 to January 2011, 54 patients with active LN (47
females, 7 males) followed in two Italian renal units
(Ospedale Maggiore Ca’ Granda and Ospedale San Carlo
Borromeo, Milano) entered this open prospective study.
Fifty patients were Caucasian, two were Asian and two
were Hispanic. At first presentation, all patients fit the diag-
nosis of SLE according to the ACR criteria [24]. The mean
age at diagnosis of LN was 31.4 years (S.D. 11.3). SLE was
diagnosed at 49.6 months (S.D. 64.1) before the diagnosis
of LN. Three patients were not submitted to renal biopsy for
severe thrombocytopenia, while in the other patients renal
biopsy showed class III in 9, class IV in 26, class V in 2,
class III + V in 4 and class IV + V in 10 according to the
International Society of Nephrology (ISN)/Renal
Pathology Society (RPS) classification [25]. Twenty-seven
patients entered the study at the diagnosis of LN, the other
22 patients at the diagnosis of a new flare of LN and 5
patients for refractory renal disease. Ten of these patients
have previously been reported [16].
Endpoints of the study
Primary endpoints
The primary endpoints were renal response at 3 months
and complete renal remission at 12 months.
Secondary endpoints
The secondary endpoints were response of clinical and
biochemical extra-renal parameters and side effects.
Definitions
(i) Renal response at 3 months: improvement of
serum creatinine if impaired at baseline and reduc-
tion of 50% of proteinuria and of microscopic
haematuria.
(ii) Complete renal remission at 12 months: serum
creatinine <1.2 mg/dl (or return to the baseline value
in patients with chronic renal dysfunction) and protein-
uria <0.5 g/24 h and <5 urinary erythrocytes (UE)/high
power field (HPF).
(iii) Partial renal remission at 12 months: serum creatin-
ine <1.2 mg/dl (or return to the baseline value in
patients with chronic renal dysfunction) and pro-
teinuria of 0.52 g/day.
(iv) No response: no improvement in proteinuria or in
serum creatinine if impaired at baseline.
(v) Acute renal dysfunction: increase of serum creatin-
ine to >1.2 mg/dl and creatinine clearance
<75 ml/min.
(vi) Chronic renal insufficiency: doubling of plasma cre-
atinine lasting for at least 6 months with a value of
plasma creatinine >2 mg/dl and creatinine clear-
ance <40 ml/min without any improvement over
time.
Methods
Global disease activity was evaluated using the
SLEDAI [26].
Statistical methods
For comparison of variables at baseline and at follow-up
Student’s t-test was used for normally distributed param-
eters, the non-parametric MannWhitney test was used
for non-normally distributed parameters and the chi-
square test was used for dichotomized variables.
Therapeutic schedules
At enrolment, all specific therapies were stopped with the
exception of HCQ and the patients received one i.v. MPP
(0.5 g for body weight <50 kg, 1 g for weight >50 kg) for
3 consecutive days followed by prednisone 0.50.75 mg/
kg/day for 1 month, then progressively tapered at the dis-
cretion of the clinicians; and RTX 1 g i.v. at the end of the
third infusion of MPP and at day 18 (patients received
standard premedication with antihistamine and paraceta-
mol); or MMF 22.5 g/day or six i.v. CYC pulses of 0.5
each, one every fortnight [27].
At the beginning of the fourth month, as maintenance
therapy, in addition to prednisone patients received AZA
12 mg/kg/day or MMF 12 g/day or ciclosporin 12 mg/
kg/day. The kind of treatment was chosen on the basis of
patient choice or the physician’s clinical judgment. Written
consent according to the Declaration of Helsinki was
obtained from all subjects. Approval from the local ethics
committee was not sought because therapy regimens
were in compliance with standards currently applied in
Italy and because of the observational nature of the study.
Results
Characteristics of the three groups of patients at
the beginning of the study
Seventeen patients (15 females, 2 males) were treated
with RTX, 17 patients (15 females and 2 male) with MMF
and 20 patients (17 females and 3 males) with CYC
pulses. Three patients on RTX, 10 on MMF, and 14
on CYC pulses entered the study at diagnosis of LN.
The duration of SLE before the diagnosis of LN was
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4.62 years (S.D. 6.51, median 1.52). Eleven patients on
RTX, seven on MMF and four in the CYC group entered
the study at diagnosis of a new renal flare. Before the renal
flare, 4 of the 11 patients of the RTX group were in com-
plete remission, 6 in partial remission and 1 with stable
chronic renal insufficiency. Of the seven patients in the
MMF group, two were in complete remission, three in par-
tial remission and two had stable chronic renal insuffi-
ciency (serum creatinine 2.1 and 2.6 mg/dl and
proteinuria 0.23 and 0.36 g/day, respectively). Of the four
in the CYC group, three were in complete remission and
one in partial remission. Three patients in the RTX group
and two in the CYC group entered the study for refractory
renal disease. Before entering the study, all these patients
were receiving treatment with low-dose steroids asso-
ciated with AZA in six, MMF in seven, ciclosporin in
three and MTX in one.
In comparison to patients treated with MMF, patients
who received RTX had a significantly longer duration of
SLE [12.82 years (S.D. 6.3) vs 6.96 (5.82), P= 0.008] and LN
[7.1 years (S.D. 4.54) vs 3.1 (3.73), P= 0.008], had a signifi-
cantly higher number of renal flares before entering the
study [2.5 (S.D. 1.5) vs 0.82 (1.19), P= 0.01] and had a
higher activity index at renal biopsy [7.25 (S.D. 2.7) vs 4.4
(3.41), P= 0.037] (Table 1).
Compared with patients treated with CYC pulses, pa-
tients who received RTX were significantly older when
entering this study [38.4 years (S.D. 6.9) vs 32.05 (8.43),
P= 0.02], had significantly longer duration of SLE (12.82
years (S.D. 6.3) vs 5.26 (6.8), P= 0.001] and LN [7.1 years
(S.D. 4.54) vs 1.62 (4.7), P= 0.000], had a significantly
greater number of renal flares before entering the study
[2.5 (S.D. 1.5) vs 0.2 (0.41), P= 0.000] and had a higher
chronicity index at renal biopsy [1.6 (S.D. 1.7) vs 0.8 (1.1),
P= 0.05] (Table 1).
At the beginning of the study there were no significant
differences in the mean value of serum creatinine, protein-
uria, number of red blood cells at urinary sediment score
between patients treated with RTX and those treated with
MMF and those with CYC pulses, although the mean
value of proteinuria was higher and the mean value of
serum albumin was lower in the RTX group compared
with the other groups. Four patients on RTX (23.5%) had
acute renal dysfunction (in one superimposed with pre-
existing chronic renal insufficiency) compared with four
on MMF (23.5%) (in two superimposed with pre-exsisting
chronic renal insufficiency) and three in the CYC group
(15%). Nephrotic syndrome was present in 10 patients
on RTX (59%) in 8 on MMF (47%) and in 8 in the CYC
group (40%) (P-value not significant).
There were no significant differences between RTX and
MMF and between RTX and the CYC group in the per-
centage of patients with albumin <3.5 g/dl (93% vs 64.7%
and vs 61.1%, P-value not significant), in C3 <90 mg/dl
TABLE 1 Comparison between characteristics of patients treated with RTX, MMF and CYC
MMF (n= 17) RTX (n= 17)
CYC
(n= 20)
P-value
RTX vs
MMF
P-value
RTX vs
CYC
Sex, F/M 15/2 15/2 17/3 0.6 0.8
Age at diagnosis of LN, mean (S.D.), years 32.35 (17.75) 31.09 (9.48) 31.0 (8.34) 0.8 0.97
Age at the beginning of the study, mean (S.D.), years 34.76 (15.2 38.4 (6.9) 32.05 (8.43) 0.37 0.02
Duration of SLE, mean (S.D.), years 6.96 (5.82) 12.82 (6.3) 5.26 (6.8) 0.008 0.001
Duration of LN, mean (S.D.), years 3.1 (3.73) 7.1 (4.54) 1.62 (4.7) 0.008 0.000
Previous therapy, no therapy/P alone/P + AZA/
P + CYC/P + MMF/P + CsA/P + MTX, n
5/4/4/6/0/0/2 1/0/8/10/8/7/2 7/4/5/3/4/1/1 0.01 0.007
Number of flares, mean (S.D.) 0.82 (1.19) 2.5 (1.5) 0.2 (0.41) 0.01 0.000
Therapy at enrolment, no therapy/P alone/P + AZA/
P + MMF/P + CsA, n
6/7/3/0/0 1/5/3/5/3 8/7/2/3/0 0.018 0.05
Class III/IV/V/V + III/V + IV, n 4/7/1/2/0 (3 NA) 1/11/1/0/4 4/8/0/2/6 0.07 0.2
Activity index, mean (S.D.) 4.4 (3.41) 7.25 (2.7) 6.9 (2.43) 0.037 0.68
Chronicity index, mean (S.D.) 0.9 (0.99) 1.6 (1.7) 0.8 (1.1) 0.15 0.05
Serum creatinine, mean (S.D.), mg/dl 1.2 (0.99) 1.08 (0.8) 0.94 (0.34) 0.7 0.5
GFR, mean (S.D.), ml/min 88.4 (40.5) 89.75 (35.9) 95.25 (38.3) 0.9 0.65
Proteinuria, mean (S.D.), g/day 3.5 (2.9) 4.5 (2.9) 3.28 (2.2) 0.3 0.15
Urinary red blood cells, mean (S.D.) 33 (46.5) 44.7 (44.4) 40.9 (25.6) 0.45 0.7
Albuminaemia, mean (S.D.), g/dl 3 (0.81) 2.85 (0.32) 3.2 (1.05) 0.48 0.19
Haemoglobin, mean (S.D.), g/dl 11.2 (2.0) 11.8 (1.58) 11.0 (2.2) 0.33 0.2
C3, mean (S.D.), mg/dl 63.5 (28.6) 63.3 (28.2) 61.4 (29.6) 0.98 0.8
C4, mean (S.D.), mg/dl 10.3 (6.7) 8.9 (6.4) 8.8 (5.4) 0.5 0.9
Anti-DNA antibodies, mean (S.D.), U/ml 168 (140.1) 216.6 (122.0) 184.5 (134.3) 0.3 0.4
SLEDAI, mean (S.D.) 15.1 (6.45) 14.1 (4.53) 18.35 (4.8) 0.6 0.01
P after MPP, mean (S.D.), mg/day 39.9 (14.6) 26.3 (6.5) 37.7 (12) 0.01 0.001
P after MPP, mean (S.D.), mg/kg/day 0.66 (0.28) 0.42 (0.1) 0.62 (0.21) 0.002 0.001
F/M: females/males; P: prednisone; CsA: ciclosporin A; GFR: glomerular filtration rate; MPP: methylprednisolone pulse.
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(76.4% vs 76.4% and vs 78.9%, P-value not significant), in
C4 <15 mg/dl (76.4% vs 58.8% and vs 78.9%, P-value not
significant) and in haemoglobin <12 g/dl (47% vs 64.7%
and vs 70.9%, P-value not significant).
After MPP the mean basal dosage of prednisone
was significantly lower in patients on RTX [26.3 mg/day
(S.D. 6.5) and 0.42 mg/kg/day (S.D. 0.1)] than on MMF
[39.9 mg/day (S.D. 14.6), P= 0.01 and 0.66 mg/kg/day
(S.D. 0.2), P= 0.002] and in the CYC group [37.7 mg/day
(S.D. 120.0), P= 0.001 and 0.62 mg/kg/day (S.D. 0.21),
P= 0.001]. The dosage of prednisone continued to
be lower in the RTX group than in the MMF and CYC
groups until the third month. From the 3rd month to the
12th month the mean dosage of oral prednisone was not
different among the three groups (Table 2).
Outcome of the three groups
At 3 and 12 months significant improvement in almost all
the parameters evaluated was observed in all groups
(Tables 3 and 4). At 3 months, renal response occurred
in 10 patients (58.8%) on RTX, in 11 (64.7%) on MMF and
in 12 of 19 (63.1%) in the CYC group (P-value not
significant).
At the beginning of the fourth month MMF was given to
73.3% of patients in the RTX group and to 53% in the
CYC group, AZA was given to 13.3% in the RTX group
and to 35% in the CYC group and ciclosporin A was given
to 13.3% in the RTX group and 11.8% in the CYC group.
All patients in the MMF group continued the same
therapy.
At 12 months, 12 patients on RTX (70.6%) were in com-
plete remission, compared with 9 (52.9%) on MMF and 13
(65%) in the CYC group. Partial remission was observed in
five patients on RTX (29.4%), seven (41.1%) on MMF and
five (25%) in the CYC group. One patient on MMF (5.9%)
and two in the CYC group (10%) had no response. At 12
months, serum albumin was <3.5 g/dl in none of the pa-
tients on RTX, in three on MMF and in two in the CYC
group. C3 was <90 mg/dl and C4 <15 mg/dl, respectively,
in 9 and 8 patients on RTX, in 8 and 3 on MMF and in 10
and 12 in the CYC group (P-value not significant). Anti-
DNA antibodies continued to be positive in nine patients
on RTX, four on MMF and eight in the CYC group.
The SLEDAI score progressively decreased in all groups
without differences between groups. Table 4 reports the
response to therapy of the extra-renal manifestations of
SLE in the three groups at baseline, 3 and 12 months. Skin
and joint manifestations progressively improved in all
groups while haematological manifestations, in particular
anaemia, persisted in one third of patients in each group.
No patients died or developed renal or extra-renal flares
during the observation period.
Immunological parameters and histological classes
at renal biopsy as predictors of response/remission
in the RTX group
Anti-DNA antibodies were positive at the baseline in 15 of
17 patients treated with RTX. Of these, 60% achieved
response at 3 months, compared with neither of the two
patients with negative anti-DNA antibodies. At 12 months,
73% of the patients with positive anti-DNA antibodies
were in complete remission, compared with 50% of
those with negative anti-DNA antibodies at baseline. The
differences were not significant; however, the mean
values of anti-DNA antibodies at baseline in patients
who achieved remission tended to be higher [243.9 (S.D.
125.6)] compared with those of patients who did not
achieve remission [125.2 (S.D. 86.1), P= 0.1]. Thirteen of
17 patients (76.5%) treated with RTX had low complement
fractions (C3 and/or C4) at baseline. Of these, nine
achieved response at 3 months (69%), compared with
one of the four (25%) patients with normal complement.
At 12 months, 10 of the 13 patients (77%) with low com-
plement were in complete remission, compared with two
of the four (50%) with normal complement. The differ-
ences were not significant.
No significant differences emerged in response/
remission to RTX of the different histological classes at
renal biopsy. Of the 11 patients in class IV, 72% achieved
response at 3 months and 82% achieved complete remis-
sion at 12 months, while of the four patients in class IV + V,
only one (25%) achieved response at 3 months and two
(50%) entered complete remission at 12 months. The only
patient in class III did not achieve response at 3 months
and achieved partial remission at 12 months. Instead, the
patient in class V achieved a response at 3 months and
then achieved complete remission at 12 months.
Side effects
In the RTX group, one patient had an allergic reaction at
the second infusion, two patients had a mild infection
(flu syndrome and gastroenteritis) a few weeks after RTX
infusion, one patient had otitis and a gluteal abscess and
another patient complained of diffuse pruritus for some
TABLE 2 Comparison of prednisone dosages in patients treated with RTX, MMF and CYC
Prednisone, mg/day Baseline 1 month 2 months 3 months 6 months 12 months
RTX 26.3 (6.5) 21.7 (7.7) 20.7 (5.8) 17.9 (6.8) 13.2 (3.7) 8.8 (2.7)
MMF 36.9 (14.6) 27.1 (10.3) 22.2 (10.3) 17.2 (6.4) 12.4 (4.4) 8.01 (4.3)
CYC 37.7 + 12 30.9 + 9.9 26.2 + 10.9 17.5 + 8.45 11.03 + 6.13 8.5 + 7.9
P: (RTX vs MMF) 0.01 0.09 0.6 0.7 0.5 0.5
P: (RTX vs CYC) 0.001 0.008 0.08 0.8 0.2 0.9
Values are given as mean (S.D.).
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weeks. In the MMF group, three patients developed
diarrhoea (in one associated with leucopenia) requiring
reduction of the MMF dosage, one patient developed
pneumonia, acute rhinitis and diarrhoea, and another
patient developed varicella zoster. In the CYC group,
two patients developed leucopenia, one patient de-
veloped severe anaemia requiring blood transfusion, one
patient developed acute gastroenteritis, one patient had
two episodes of urinary sepsis and two patients had
herpes zoster. Three patients developed amenorrhoea,
transient in one patient and persistent in the other two
patients.
Outcome of the patients beyond month 12
Follow-up beyond 12 months (Table 5) was shorter in pa-
tients who received RTX compared with those treated
with CYC (30.5 vs 51.8 months, P= 0.03), and not different
from those of patients treated with MMF (30.5 vs 32.3,
P= 0.8). At last observation there were no significant dif-
ferences among the three groups in the mean values of
serum creatinine and proteinuria. However, the number of
patients who developed flares was higher in the CYC
group than in the other two groups. No patients entered
end-stage renal disease and no patients died.
Discussion
Based on the available data on the treatment of LN, RTX
emerged as ineffective in prospective trials [8, 28] but
beneficial in clinical practice [10]. In fact, the LUNAR trial
[8] failed to demonstrate the efficacy of RTX as an add-on
therapy to steroids and MMF in incident LN patients.
Instead, a recent pooled analysis [11] of 164 patients
with LN who received RTX in European centres for dis-
eases refractory to standard therapy or for renal flares
documented complete response in 30% and partial re-
sponse in 37% of patients at 12 months. A higher rate of
response was achieved in patients with class III (81%) and
mixed forms (75%) compared with classes IV (63%) and V
(65%). Nephrotic syndrome and renal dysfunction have
been reported to be predictive of poor response to RTX
therapy [11, 22]. Moreover, recent studies suggest that the
concomitant use of RTX and CYC may not provide add-
itional benefit to RTX alone [29, 30]. RTX emerged as a
steroid sparing agent in two studies [23, 31]. In another
prospective cohort of patients who received a regimen
based on RTX and MMF without steroids the majority of
patients achieved renal remission [32]. Histological im-
provement at repeated renal biopsy in terms of a signifi-
cant reduction of the activity index was reported by some
authors [30, 33, 34]. However, the efficacy of RTX not
associated with other immunosuppressive drugs has
never been compared with that of CYC pulses and MMF,
drugs that are considered to be the standard of care for the
treatment of severe forms of this disease. In this observa-
tional study we present the results of the first comparison
of RTX vs MMF and vs CYC pulses in the treatment of
active LN. We used the RA regimen for RTX because it
seems to be equally effective as the haematological
schedule and because it implies only two hospital admis-
sions. All patients received MMP before RTX, MMF and
CYC pulses. After 3 months a maintenance therapy was
added in all three groups with the aim of consolidating the
response and preventing the well-documented recur-
rences of the disease after RTX therapy [13]. As mainten-
ance treatment we employed MMF or AZA or ciclosporin,
as all these drugs appeared to be equally effective in main-
tenance therapy, at least in European patients [35, 36]. The
majority of patients treated with RTX entered the study at
the diagnosis of a new renal flare while the majority of pa-
tients on MMF and in the CYC group entered the study at
the diagnosis of LN. As a consequence, the durations of
SLE and LN were longer in the RTX group than in the other
groups. In addition, patients treated with RTX had other
negative prognostic factors: they were older and had a
higher chronicity index than those who received CYC,
and had a higher activity index than patients treated with
MMF. At the beginning of the study there was a trend of
higher proteinuria and lower serum albumin in the RTX
group compared with the other groups.
TABLE 5 Clinical status at the last observation of patients treated with RTX, MMF or CYC
MMF RTX CYC
Follow-up beyond month 12, mean (S.D.) 32.3 (36.1) 30.52 (21.1) 51.8 (30.6)
Serum creatinine, mean (S.D.), mg/dl 0.98 (0.76) 1 (0.8) 0.99 (0.45)
Proteinuria, mean (S.D.), g/day 0.4 (0.31) 0.6 (0.66) 0.8 (0.75)
Proteinuria >0.5 g/day, n (%) 2 (11.8) 2 (11.8) 5 (25)
Chronic renal insufficiency, n (%) 2 (11.8)a 1 (5.9)a 1 (5)b
End-stage renal disease, n (%) 0 0 0
Extra-renal flares, n (%) 0 1 (5.9) 4 (20)
Proteinuric flares, n (%) 1 (5.9) 1 (5.9) 7 (35)c
Nephritic flares, n (%) 0 0 1 (5)
Months from the end of the study to flares 4 6 Mean 22 (S.D. 10.2),
range 836
Follow-up beyond month 12: RTX vs MMF, P= 0.8; RTX vs CYC, P= 0.03; MMF vs CYC, P= 0.09. No other significant
differences were found between groups for the other variables of the table. aPatients with renal insufficiency at the beginning
of the study. bPatient who developed renal insufficiency during the study. cOne flare was due to non-compliance with therapy.
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Three months after the beginning of the induction ther-
apy, renal response occurred with the same frequency in
all groups. Of note, these results were achieved with a
lower dosage of prednisone during the first 3 months in
the RTX group compared with those in the CYC and MMF
groups. At 12 months, clinical renal remission (complete
or partial) was achieved in all patients treated with RTX
and in all but one patient in the MMF group and two in the
CYC group. However, due to the lack of control renal
biopsies, we cannot exclude persistent histological activ-
ity in these patients.
In addition, a significant and comparable improvement
in all the other clinical and biochemical parameters eval-
uated was documented in all groups with the exception of
haematological abnormalities, which persisted in around
one third of patients in each group.
Side effects seem to be more frequent in the CYC group
than in the RTX and MMF groups. Patients have been
followed 2.5 to 4 years (mean of 40 months) since the
end of the study. At last observation, the mean serum
creatinine was in the normal range and the mean protein-
uria was <1 g/day in all groups. Patients treated with CYC
developed more renal and extra-renal flares than the other
two groups. This negative result could be due to the
longer follow-up of these patients compared with those
in the RTX and MMF groups. Due to the small number
of patients included in the RTX group, we were unable
to demonstrate a different outcome of the histological
classes at renal biopsy as well as a different response to
therapy of patients with low or normal complement frac-
tions and in those with positive or negative anti-DNA
antibodies.
Our study has some limitations, in particular, the sample
size was small, it was not a randomized trial and the de-
cision to assign the patient to one or another group was
based on clinical judgment, in particular, patients that
have received one or more courses of CYC or MMF
entered the RTX group. For all these reasons, our results
need to be confirmed in larger randomized trials.
However, the results are quite encouraging and seem to
indicate that RTX is at least as effective as MMF 22.5 g/
day and 3 g CYC pulses in inducing remission in the ma-
jority of patients with active LN. The addition of a main-
tenance therapy at the beginning of the fourth month
consolidated the results and achieved the goal of com-
plete remission in the majority of patients. Similar results
have been shown in RCTs in systemic vasculitis [37],
where RTX has been shown to be equivalent to or even
more effective than CYC, particularly in recurrent forms.
This is particularly important in situations where CYC
avoidance is desirable, such as in young patients, to pre-
serve fertility, if previously treated with CYC, in patients
intolerant to MMF or CYC and in refractory cases.
Rheumatology key messages
. Rituximab (RTX) seems to be as effective as stand-
ard treatment in active LN.
. RTX might induce LN remission with a lower
dosage of corticosteroids.
Acknowledgements
We would like to thank Andrea Centa and Marina
Balderacchi for their secretarial assistance.
Funding: The work was supported by the Project in
Glomerulonephritis grant in memory of Pippo Neglia.
Disclosure statement: R.A.S. received consultant fees
from Roche. All other authors have declared no conflicts
of interest.
References
1 Bertsias GK, Tektonidou M, Amoura Z et al. European
League Against Rheumatism and European Renal
Association-European Dialysis and Transplant Association
Joint European League Against Rheumatism and
European Renal Association-European Dialysis and
Transplant Association (EULAR/ERA-EDTA) recommen-
dations for the management of adult and paediatric lupus
nephritis. Ann Rheum Dis 2012;71:177182.
2 Henderson LK, Masson P, Craig JC et al. Induction and
maintenance treatment of proliferative lupus nephritis: a
meta-analysis of randomized controlled trials. Am J
Kidney Dis 2013;61:7487.
3 Liu LL, Jiang Y, Wang LN et al. Efficacy and safety of
mycophenolate mofetil versus cyclophosphamide for
induction therapy of lupus nephritis: a meta-analysis of
randomized controlled trials. Drugs 2012;72:152133.
4 Lee YH, Woo JH, Choi SJ et al. Induction and mainten-
ance therapy for lupus nephritis: a systematic review and
meta-analysis. Lupus 2010;19:70310.
5 Chan TM. Mycophenolate mofetil in the treatment of lupus
nephritis—7 years on. Lupus 2008;17:61721.
6 Walsh M, Solomons N, Lisk L et al. Mycophenolate mofetil
or intravenous cyclophosphamide for lupus nephritis with
poor kidney function: a subgroup analysis of the Aspreva
Lupus Management Study. Am J Kidney Dis 2013;61:
7105.
7 Tang Z, Yang C, Yu C et al. Effects of mycophenolate
mofetil in patients with crescentic lupus nephritis.
Nephrology 2008;13:7027.
8 Furie R, Looney RJ, Rovin B et al. Efficacy and safety of
rituximab in subjects with active proliferative lupus neph-
ritis (LN): results from the randomized, double-blind phase
III LUNAR Study [abstract]. Arthritis Rheum 2009;60:S429.
9 Weidenbusch M, Ro¨mmele C, Schro¨ttle A et al. Beyond
the LUNAR trial. Efficacy of rituximab in refractory lupus
nephritis. Nephrol Dial Transplant 2013;28:10611.
10 Ramos-Casals M, Soto MJ, Cuadrado MJ et al. Rituximab
in systemic lupus erythematosus: a systematic review of
off-label use in 188 cases. Lupus 2009;18:76776.
11 Dı´az-Lagares C, Croca S, Sangle S et al. The UK-
BIOGEAS Registry. Efficacy of rituximab in 164 patients
with biopsy-proven lupus nephritis: Pooled data from
European cohorts. Autoimmun Rev 2012;11:35764.
12 Terrier B, Amoura Z, Ravaud P et al. Safety and efficacy of
rituximab in systemic lupus erythematosus: results from
136 patients from the French autoimmunity and rituximab
registry. Arthritis Rheum 2010;62:245866.
1576 www.rheumatology.oxfordjournals.org
Gabriella Moroni et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/rheum
atology/article-abstract/53/9/1570/1872972 by U
niversità degli Studi di M
ilano user on 11 O
ctober 2018
13 Ramos-Casals M, Diaz-Lagares C, Soto-Cardenas MJ
et al. Rituximab therapy in lupus nephritis: current clinical
evidence. Clin Rev Allergy Immunol 2011;40:15969.
14 Sfikakis PP, Boletis JN, Lionaki S et al. Remission of
proliferative lupus nephritis following B cell depletion
therapy is preceded by down-regulation of the T cell
costimulatory molecule CD40 ligand: an open-label trial.
Arthritis Rheum 2005;52:50113.
15 Camous L, Melander C, Vallet M et al. Complete remission
of lupus nephritis with rituximab and steroids for induction
and rituximab alone for maintenance therapy. Am J Kidney
Dis 2008;52:34652.
16 Moroni G, Gallelli B, Sinico RA et al. Rituximab versus oral
cyclophosphamide for treatment of relapses of prolifera-
tive lupus nephritis: a clinical observational study. Ann
Rheum Dis 2012;71:17512.
17 Gunnarsson I, Sundelin B, Jo´nsdo´ttir T et al.
Histopathologic and clinical outcome of rituximab treat-
ment in patients with cyclophosphamide-resistant prolif-
erative lupus nephritis. Arthritis Rheum 2007;56:126372.
18 Leandro MJ, Cambridge G, Edwards JC et al. B-cell
depletion in the treatment of patients with systemic lupus
erythematosus: a longitudinal analysis of 24 patients.
Rheumatology 2005;44:15425.
19 van Vollenhoven RF, Gunnarsson I, Welin-Henriksson E
et al. Biopsy-verified response of severe lupus nephritis to
treatment with rituximab (anti-CD20 monoclonal antibody)
plus cyclophosphamide after biopsy-documented failure
to respond to cyclophosphamide alone. Scand J
Rheumatol 2004;33:4237.
20 Roccatello D, Sciascia S, Rossi D et al. Intensive short-
term treatment with rituximab, cyclophosphamide and
methylprednisolone pulses induces remission in severe
cases of SLE with nephritis and avoids further immuno-
suppressive maintenance therapy. Nephrol Dial
Transplant 2011;26:398792.
21 Vigna-Perez M, Herna´ndez-Castro B, Paredes-
Saharopulos O et al. Clinical and immunological effects of
rituximab in patients with lupus nephritis refractory to
conventional therapy: a pilot study. Arthritis Res Ther
2006;8:R83.
22 Boletis JN, Marinaki S, Skalioti C et al. Rituximab and
mycophenolate mofetil for relapsing proliferative lupus
nephritis: a long-term prospective study. Nephrol Dial
Transplant 2009;24:215760.
23 Pepper R, Griffith M, Kirwan C et al. Rituximab is an ef-
fective treatment for lupus nephritis and allows a reduction
in maintenance steroids. Nephrol Dial Transplant 2009;24:
371723.
24 Hochberg MC. Updating the American College of
Rheumatology revised criteria for the classification
of systemic lupus erythematosus. Arthritis Rheum 1997;
40:1725.
25 Weening JJ, D’Agati VD, Schwartz MM et al. The classi-
fication of glomerulonephritis in systemic lupus erythe-
matosus revisited. Am Soc Nephrol 2004;15:24150.
26 Bombardier C, Gladman DD, Urowitz MB et al. Derivation
of the SLEDAI. A disease activity index for lupus patients.
The Committee on Prognosis Studies in SLE. Arthritis
Rheum 1992;35:63040.
27 Houssiau FA, Vasconcelos C, D’Cruz D et al. The 10-year
follow-up data of the Euro-Lupus Nephritis Trial compar-
ing low-dose and high-dose intravenous cyclophospha-
mide. Ann Rheum Dis 2010;69:614.
28 Merrill JT, Neuwelt CM, Wallace DJ et al. Efficacy and
safety of rituximab in moderately-to-severely active sys-
temic lupus erythematosus: the randomized, double-blind,
phase II/III systemic lupus erythematosus evaluation of
rituximab trial. Arthritis Rheum 2010;62:22233.
29 Lu TY, Ng KP, Cambridge G et al. A retrospective seven-
year analysis of the use of B cell depletion therapy in
systemic lupus erythematosus at University College
London Hospital: the first fifty patients. Arthritis Rheum
2009;61:4827.
30 Li EK, Tam LS, Zhu TY et al. Is combination rituximab with
cyclophosphamide better than rituximab alone in the
treatment of lupus nephritis? Rheumatology 2009;48:
8928.
31 Ezeonyeji AN, Isenberg DA. Early treatment with rituximab
in newly diagnosed systemic lupus erythematosus
patients: a steroid-sparing regimen. Rheumatology 2012;
51:47681.
32 Condon MB, Ashby D, Pepper RJ et al. Prospective
observational single-centre cohort study to evaluate the
effectiveness of treating lupus nephritis with rituximab and
mycophenolate mofetil but no oral steroids. Ann Rheum
Dis 2013;72:12806.
33 Melander C, Salle´e M, Trolliet P et al. Rituximab in severe
lupus nephritis: early B-cell depletion affects long-term
renal outcome. Clin J Am Soc Nephrol 2009;4:57987.
34 Jo´nsdo´ttir T, Zickert A, Sundelin B et al. Long-term
follow-up in lupus nephritis patients treated with
rituximab—clinical and histopathological response.
Rheumatology 2013;52:84755.
35 Houssiau FA, D’Cruz D, Sangle S et al. Azathioprine
versus mycophenolate mofetil for long-term immunosup-
pression in lupus nephritis: results from the MAINTAIN
Nephritis Trial. Ann Rheum Dis 2010;69:20839.
36 Moroni G, Doria A, Mosca M et al. A randomized pilot trial
comparing cyclosporine and azathioprine for maintenance
therapy in diffuse lupus nephritis over four years. Clin J Am
Soc Nephrol 2006;1:92532.
37 Stone JH, Merkel PA, Spiera R et al. Rituximab versus
cyclophosphamide for ANCA-associated vasculitis.
N Engl J Med 2010;363:22132.
www.rheumatology.oxfordjournals.org 1577
Rituximab in lupus nephritis
D
ow
nloaded from
 https://academ
ic.oup.com
/rheum
atology/article-abstract/53/9/1570/1872972 by U
niversità degli Studi di M
ilano user on 11 O
ctober 2018
